Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide (used in Ozempic/Wegovy) is a good example of this. Plant-based peptides are extracted from plant proteins but still carry specific amino acid sequences that can trigger meaningful ...

which separates prohormones at specific amino acid sequences and is known to be involved in human obesity. One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite ...

As the popularity of peptides continues to rise in 2025, fueled by the success of GLP-1 medications like Semaglutide and Tirzepatide, more individuals are exploring their potential health benefits ...

"The receptors targeted by semaglutide are found ... 1/3 would generate 2,683 unique peptides from the 373 proteins. Coassolo ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (sold as Ozempic or Wegovy), mimic ... gene expression that are not attributable to modification of the DNA sequence itself.